Results 141 to 150 of about 2,862,567 (165)

Low prevalence of archived integrase strand transfer inhibitors resistance associated mutations in Botswana before the roll out of dolutegravir based first line antiretroviral therapy. [PDF]

Front Microbiol
Maruapula D, Ditshwanelo D, Pema MN, Bareng OT, Choga WT, Moraka NO, Mokgethi PT, Seatla KK, Koofhethile CK, Zuze BJ, Gaolathe T, Pretorius-Holme M, Lebani K, Makhema J, Novitsky V, Shapiro R, Lockman S, Moyo S, Gaseitsiwe S.   +18 more
europepmc   +1 more source

The differential effects of integrase strand transfer inhibitors and efavirenz on neuropsychiatric conditions and brain imaging in HIV-positive men who have sex with men. [PDF]

Biosaf Health
He Y, Zhang Y, Zhen J, Sun G, Li Z, Yang B, Yang B, Chang K, Chen X, Zhang Y, Guo C, Wang W, Wu P, Zhang T, Wang L.   +14 more
europepmc   +1 more source

Energy balance and body composition after switch between integrase strand transfer inhibitors and doravirine among people with HIV. [PDF]

J Antimicrob Chemother
Erlandson KM, Mohaweche R, Morrow M, Mawhinney S, Khuu V, Boyd M, Balasubramanyam A, Melanson EL, Lake JE.   +8 more
europepmc   +1 more source

Metabolic Complications Associated with Use of Integrase Strand Transfer Inhibitors (InSTI) for the Treatment of HIV-1 Infection: Focus on Weight Changes, Lipids, Glucose and Bone Metabolism. [PDF]

Curr HIV/AIDS Rep
Savinelli S, Newman E, Mallon PWG.
europepmc   +1 more source

Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as novel HIV-1 integrase strand transfer inhibitors. [PDF]

RSC Adv
Zhang RH, Chen GQ, Wang W, Wang YC, Zhang WL, Chen T, Xiong QQ, Zhao YL, Liao SG, Li YJ, Yan GY, Zhou M.   +11 more
europepmc   +1 more source

<i>N</i>-Substituted Bicyclic Carbamoyl Pyridones: Integrase Strand Transfer Inhibitors that Potently Inhibit Drug-Resistant HIV-1 Integrase Mutants. [PDF]

ACS Infect Dis
Mahajan PS, Smith SJ, Li M, Craigie R, Hughes SH, Zhao XZ, Burke TR.   +6 more
europepmc   +1 more source

Cardiometabolic Differences in People Living with HIV Receiving Integrase Strand Transfer Inhibitors Compared to Non-nucleoside Reverse Transcriptase Inhibitors: Implications for Current ART Strategies. [PDF]

Viruses
Vos WAJW, Vadaq N, Matzaraki V, Otten T, Groenendijk AL, Blaauw MJT, van Eekeren LE, Brinkman K, de Mast Q, Riksen NP, Stalenhoef AFH, van Lunzen J, van der Ven AJAM, Blok WL, Stalenhoef JE.   +14 more
europepmc   +1 more source

Predictive Efficacy of Dual Therapies Combining Integrase Strand Transfer Inhibitors with Second-Generation Non-Nucleoside Reverse Transcriptase Inhibitors Following HIV-1 Treatment Failure in Cameroon: Implications for the Use of a Long-Acting Therapeutic Strategy in Low- and Middle-Income Countries. [PDF]

Viruses
Gouissi Anguechia DH, Bouba Y, Semengue ENJ, Ka'e AC, Takou D, Ambe Chenwi C, Beloumou G, Nka AD, Basseck Wome UR, Santoro MM, Ceccherini-Silberstein F, Chatté A, Montesano C, Cappelli G, Colizzi V, Ndjolo A, Mbanya D, Ndembi N, Perno CF, Fokam J.   +19 more
europepmc   +1 more source

Incidence of low-level viremia and its impact on virologic failure among people living with HIV who started an integrase strand transfer inhibitors: a longitudinal cohort study. [PDF]

BMC Infect Dis
Lao X, Zhang H, Deng M, Li Q, Xiao Q, He L, Ma L, Song A, Liang X, Yu F, Zhao H, Zhang F.   +11 more
europepmc   +1 more source